BIOTECH

BIOTECH

Stalicla Secures $17.4 Million in Series B Financing

Stalicla SA, a clinical-stage biopharmaceutical company advancing precision medicine pipelines for neuropsychiatric and neurological disorders,...

Read more

BIOTECH

Spexis provides business update and announces financial results for the first half of 2023

Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases...

Read more

BIOTECH

Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies

Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases...

Read more

BIOTECH

Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study

Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today...

Read more

BIOTECH

AUM Biosciences, SCG Cell Therapy, Blood And Hello Health Disclose Updates

AUM Biosciences, a Singapore-headquartered biotech company focused on precision oncology therapeutics, allotted shares worth $11.8...

Read more